Related by context. All words. (Click for frequent words.) 73 adjuvant therapy 71 tamoxifen therapy 71 hormone therapy 70 tamoxifen 68 androgen deprivation therapy 68 hormonal therapies 67 chemoradiation 67 estrogen therapy 66 androgen deprivation 65 adjuvant radiation 65 localized prostate cancer 65 trastuzumab 65 GnRH agonists 65 neoadjuvant chemotherapy 65 adjuvant chemotherapy 65 preoperative chemotherapy 65 chemoradiotherapy 64 letrozole 64 bisphosphonate therapy 64 docetaxel 64 gemcitabine 64 anastrozole 64 chemotherapy regimens 63 EBRT 63 aromatase inhibitor 63 cisplatin 63 cytotoxic chemotherapy 63 oophorectomy 63 peginterferon 62 chemotherapy regimen 62 Tamoxifen 62 zoledronic acid 62 adjuvant radiotherapy 62 cetuximab 62 prostate cancer CRPC 62 mycophenolate mofetil 62 hormonal treatments 62 cystectomy 61 hormone therapy estrogen 61 HER2 positive breast cancer 61 Adjuvant chemotherapy 61 lumpectomy 61 intravenous bisphosphonates 61 chemotherapy 61 antiplatelet therapy 61 lipid lowering therapy 61 lymph node dissection 61 aromatase inhibitor therapy 61 DMARDs 61 bevacizumab 61 cyclophosphamide 61 androgen therapy 61 imatinib 60 hormone deprivation 60 antidepressant therapy 60 HER2 negative 60 menopausal hormone therapy 60 neoadjuvant 60 androgen ablation 60 adalimumab 60 standard chemotherapy regimens 60 bilateral oophorectomy 60 pegylated liposomal doxorubicin 60 neoadjuvant therapy 60 DMARD 60 vandetanib 60 metformin 60 progestin 60 exemestane 60 premenopausal 60 estrogen progestin therapy 59 fluorouracil 59 Femara 59 carboplatin paclitaxel 59 sentinel lymph node biopsy 59 bortezomib 59 androgen suppression 59 endometrial hyperplasia 59 bisphosphonate 59 postoperative chemotherapy 59 HER2 positive metastatic breast 59 tumor recurrence 59 HER2 positive 59 Taxotere 59 azathioprine 59 endometrial cancers 59 distant metastases 59 rituximab 59 methotrexate 59 cytotoxic therapy 59 statin therapy 59 estrogen 59 immunosuppression 58 external beam radiotherapy 58 sentinel node biopsy 58 fulvestrant 58 sunitinib 58 mitoxantrone 58 corticosteroid therapy 58 hydroxychloroquine 58 5FU 58 pemetrexed 58 temozolomide 58 tibolone 58 androgen suppression therapy 58 eribulin 58 axillary dissection 58 goserelin 58 NSAIDs 58 cisplatin chemotherapy 58 DMARD therapy 58 immunosuppressive agents 58 progestins 58 metastatic breast cancer 58 anthracyclines 58 invasive carcinoma 58 bisphosphonates 58 chemotherapies 58 Cisplatin 58 relapsed ovarian cancer 58 metastatic disease 58 APTIVUS r 58 hormone blockers 58 bevacizumab Avastin 58 recurrent prostate cancer 58 Herceptin trastuzumab 58 leucovorin 58 sorafenib 58 ALND 58 methotrexate therapy 58 gefitinib 58 docetaxel chemotherapy 58 LHRH agonists 58 debulking surgery 58 biologic therapy 58 treatment regimens 58 GnRH agonist 58 severe menopausal symptoms 58 NRTIs 58 Cytoxan 58 warfarin therapy 58 FOLFOX 57 statins 57 idarubicin 57 anthracycline taxane 57 postoperative radiotherapy 57 glucocorticoids 57 interferon alfa 2b 57 monotherapy 57 prostatectomy 57 curative resection 57 breast conserving 57 dacarbazine 57 prophylactic mastectomy 57 Trastuzumab 57 chemotherapy docetaxel 57 pCR 57 pre menopausal 57 endometrial carcinoma 57 cytoreductive surgery 57 trastuzumab Herceptin ® 57 postmenopausal women 57 doxorubicin 57 sorafenib Nexavar 57 HER2 positive tumors 57 superficial bladder cancer 57 locoregional recurrence 57 TACE 57 Hormone therapy 57 allopurinol 57 recurrent ovarian cancer 57 temsirolimus 57 menopausal symptoms 57 contralateral breast 57 lenalidomide 57 EGFR mutation 57 5-FU/LV 57 metastatic castration resistant 57 DAPT 57 anti androgen 57 Torisel 57 hormone receptor positive 57 tumor shrinkage 57 Doxil ® 57 antihypertensive therapy 57 lymph node removal 57 radical prostatectomy 57 orchiectomy 57 inhaled steroids 57 endocrine therapy 57 testosterone supplementation 57 imatinib therapy 57 taxane therapy 57 oral clodronate 57 CMV disease 57 pancreatic adenocarcinoma 57 XELOX 57 metastatic RCC 57 antiangiogenic therapy 57 abiraterone 57 alkylating agent 57 virologic failure 57 IV bisphosphonates 57 cabazitaxel 56 H. pylori eradication 56 mCRC patients 56 estrogen progestin 56 colorectal liver metastases 56 brain metastases 56 capecitabine 56 cytoreduction 56 iniparib 56 letrozole Femara 56 breast cancer recurrence 56 mapatumumab 56 interferon 56 antiandrogen 56 interferon alfa 2a 56 vitamin D supplementation 56 gemcitabine Gemzar 56 FOLFIRI 56 chemopreventive agent 56 intraperitoneal chemotherapy 56 systemic corticosteroid 56 FASLODEX 56 pneumonectomy 56 anthracycline therapy 56 progestin therapy 56 protease inhibitor PI 56 differentiated thyroid 56 dutasteride 56 inhaled corticosteroids 56 estrogen receptor positive 56 beta blocker therapy 56 FOLFOX4 56 beam radiotherapy 56 abatacept 56 adriamycin 56 cervical lesions 56 gemcitabine chemotherapy 56 corticosteroids 56 clodronate 56 tamsulosin 56 bevacizumab Avastin ® 56 breast carcinoma 56 radiation therapy SBRT 56 lapatinib 56 antiviral therapy 56 neoadjuvant treatment 56 radiation therapy 56 estrogen receptor negative 56 metastatic renal cell carcinoma 56 nab paclitaxel 56 standard chemotherapy regimen 56 antiretroviral regimens 56 cilostazol 56 infliximab 56 recurrent ovarian 56 allogeneic stem cell 56 taxane chemotherapy 56 dexamethasone 56 conjugated equine estrogen 56 irinotecan 56 carboplatin 56 postmenopausal 56 pegylated interferon 56 pamidronate 56 Cristofanilli 56 erlotinib Tarceva 56 ixabepilone 55 risedronate 55 micrometastases 55 HAART 55 atypical hyperplasia 55 vasomotor symptoms 55 trastuzumab Herceptin 55 antithrombotic therapy 55 operable breast cancer 55 pertuzumab 55 antiestrogen 55 NSCLC 55 decitabine 55 oxaliplatin 55 adjuvant tamoxifen 55 pioglitazone 55 immunomodulatory therapy 55 cranial radiation 55 antiretroviral therapy 55 erlotinib 55 oral bisphosphonates 55 progestogen 55 HNSCC 55 preventive mastectomy 55 peg interferon 55 antiandrogens 55 antibiotic therapy 55 chemotherapeutic regimens 55 unresectable 55 cART 55 Combination therapy 55 HRPC 55 PREZISTA r 55 HAART regimen 55 ovarian cancer 55 chemo radiotherapy 55 Mylotarg 55 immunosuppressant drugs 55 undergone hysterectomy 55 infliximab Remicade 55 dose aspirin 55 adjuvant endocrine therapy 55 radical nephrectomy 55 advanced adenomas 55 dose cytarabine 55 FOLFOX6 55 lipid lowering drugs 55 undergoing hysterectomy 55 recurrent glioblastoma multiforme 55 lamivudine 55 abnormal mammograms 55 lenalidomide dexamethasone 55 antifungal therapy 55 menopausal symptom 55 radioiodine therapy 55 hydroxyurea 55 clinically localized prostate 55 BRCA deficient 55 chlorambucil 55 intra arterial chemotherapy 55 statin medications 55 celecoxib 55 hepatic metastases 55 heavily pretreated patients 55 Fludara 55 anticoagulation therapy 55 exemestane Aromasin 55 aromatase inhibitors 55 metastatic colorectal cancer 55 prostate cancers 55 chemotherapeutic agents 55 watchful waiting 55 cytarabine 55 adjuvant 55 interferon therapy 55 TNF inhibitors 55 contralateral breast cancer 55 HBeAg negative 55 TNF inhibitor 55 bicalutamide 55 alpha blocker 55 pomalidomide 55 bendamustine 55 fallopian tube carcinoma 55 BRCA mutation carriers 55 dose dexamethasone 55 Taxotere ® 55 serum PSA 55 alkylating agents 55 Hormonal therapy 55 LHRH agonist 55 disease progression 55 sustained virologic response 55 medically inoperable 55 statin 55 stage IIIB 55 anti TNF 55 AVODART 55 Radical prostatectomy 55 valproate 55 eptifibatide 55 salpingo oophorectomy 55 thiazide diuretics 55 dasatinib 55 epithelial ovarian cancer 55 antiretroviral regimen 55 BRCA mutations 54 teriparatide 54 chemotherapy cisplatin 54 lymphadenectomy 54 PSA screening 54 heavily pretreated 54 etoposide 54 advanced NSCLC 54 dexamethasone Decadron 54 azacitidine 54 immunosuppressive regimen 54 REVLIMID ® 54 liver metastases 54 subgroup analyzes 54 d4T 54 tyrosine kinase inhibitors 54 estrogen hormone therapy 54 fludarabine 54 paclitaxel carboplatin 54 luteinizing hormone releasing 54 lapatinib Tykerb 54 Aromasin 54 mRCC 54 alendronate 54 NNRTI 54 ovariectomy 54 metastatic colon cancer 54 selenium supplementation 54 oestrogens 54 Herceptin 54 EFAPROXYN 54 plus progestin 54 mammographic density 54 estrogens 54 calcitriol 54 biochemical recurrence 54 dual antiplatelet therapy 54 raltegravir 54 therapeutic regimens 54 Anastrozole 54 conjugated estrogen 54 BRCA mutation 54 interferon alfa 54 K ras mutations 54 lipid lowering therapies 54 motesanib 54 non squamous NSCLC 54 vinorelbine 54 hormone receptor negative 54 axillary node dissection 54 Bezielle 54 ICD implantation 54 entecavir 54 ovarian function 54 WBRT 54 resectable 54 ductal breast cancer 54 postmenopausal estrogen 54 placebo dexamethasone 54 tocilizumab 54 renal dysfunction 54 GP IIb IIIa inhibitors 54 pregabalin 54 immunosuppressant therapy 54 chemotherapeutic drugs 54 pelvic lymphadenectomy 54 hormone refractory prostate cancer 54 paricalcitol 54 atypia 54 topotecan 54 3TC lamivudine Epivir 54 antioxidant supplementation 54 adenomatous polyps 54 adalimumab Humira 54 breast tumors 54 postmenopausal hormone therapy 54 erlotinib Tarceva ® 54 fallopian tube cancers 54 androgen 54 low dose cytarabine 54 radiochemotherapy 54 nonmelanoma skin cancers 54 L dopa 54 surgical debulking 54 ribavirin therapy 54 enzastaurin 54 ABVD 54 antioxidant supplements 54 TURP 54 tamoxifen Nolvadex ® 54 metastatic prostate cancer 54 paroxysmal AF 54 anakinra 54 Tykerb 54 idraparinux 54 irinotecan chemotherapy 54 sulfasalazine 54 flutamide 54 olaparib 54 uric acid lowering 54 hypogonadal men 54 epirubicin 54 adefovir 54 urinary symptoms 54 androgen independent 54 locoregional 54 atypical ductal hyperplasia 54 SERMs 54 relapsed SCLC 54 lenalidomide Revlimid R 54 castration resistant prostate cancer 54 ibandronate 54 figitumumab 54 intravesical therapy 54 anthracycline 54 catheter angiography 54 loop diuretics 54 surgical excision 54 treat menopausal symptoms 54 EGFR inhibitors 54 LYSTEDA 54 boosted protease inhibitor 54 ARIMIDEX 54 adenoma 53 Neoadjuvant 53 bone metastases 53 lobular cancer 53 metastatic malignant melanoma 53 Xeloda 53 KRAS status 53 KRAS mutations 53 PSA velocity 53 relapsed MM 53 conjugated equine estrogens 53 calcineurin inhibitors 53 secondary amenorrhea 53 gastrointestinal stromal tumor GIST 53 Zometa 53 endometrial cancer 53 medullary thyroid cancer 53 acid suppressing 53 squamous histology 53 oral anticoagulants 53 LHRH analogues 53 paclitaxel 53 Sunitinib 53 nifedipine 53 selenium intake 53 vicriviroc 53 ALA PDT 53 preventive mastectomies 53 cardiac toxicity 53 trabectedin 53 virological failure 53 therapy HRT 53 thromboprophylaxis 53 paclitaxel Taxol 53 dacarbazine chemotherapy 53 immunosuppressive medications 53 NSAID therapy 53 cranial irradiation 53 intramuscular injections 53 bone metastasis 53 dose colchicine 53 folinic acid 53 Alessandro Riva 53 colorectal cancer 53 ganciclovir 53 thromboembolic disease 53 octreotide 53 chlamydial infection 53 refractory ovarian cancer 53 multimodality therapy 53 immunosuppressive medication 53 Erlotinib 53 antiarrhythmic drugs 53 β blockers 53 aromatase inhibitors AIs 53 Mitoxantrone 53 disease modifying antirheumatic 53 anticoagulation 53 thyroxine 53 raloxifene Evista 53 aldosterone antagonist 53 EGFR mutations 53 PSADT 53 pegfilgrastim 53 doxorubicin HCl liposome injection 53 aspirin therapy 53 post menopausal 53 endocrine therapies 53 dexrazoxane 53 axillary lymph node dissection 53 axillary nodes 53 Irinotecan 53 metastatic lung cancer 53 SLN biopsy 53 itraconazole 53 thalidomide dexamethasone 53 nonhormonal 53 prostate specific 53 oral Xeloda 53 screening mammography 53 intravenous chemotherapy 53 fluconazole 53 elevated CRP 53 olmesartan 53 trans retinoic acid 53 efavirenz Sustiva 53 nonsurgical treatments 53 imatinib Gleevec 53 prednisone 53 CsA 53 hormone refractory 53 strontium ranelate 53 overexpress HER2 53 capecitabine Xeloda 53 mTOR inhibitors 53 progesterone receptor negative 53 recurrent metastatic 53 hormonal contraception 53 invasive breast cancer 53 overlapping toxicities 53 HAART regimens 53 GISTs 53 breast cancers 53 BENICAR HCT 53 DMARDS 53 transurethral resection 53 colon tumors 53 amenorrhea 53 CaP 53 gemcitabine cisplatin 53 antihypertensive medications 53 cardiovascular morbidity 53 AGILECT R 53 gefitinib Iressa 53 cT3 prostate cancer 53 medroxyprogesterone 53 hypercalcemia 53 ductal cancer 53 BYSTOLIC 53 alteplase 53 Hycamtin 53 TTF Therapy 53 platinum refractory 53 chemotherapeutic agent 53 FOLPI 53 chemoprevention 53 endarterectomy 53 antiepileptic drugs 53 recurrences 53 metastatic kidney 53 grade gliomas 53 premenopausal women 53 ACE inhibitor 53 abnormal Pap test 53 ritonavir boosted 53 Androgen deprivation therapy 53 raloxifene 53 grade dysplasia 53 antibiotic prophylaxis 53 resistant ovarian cancer 53 NRTI backbone 53 radical cystectomy 53 myeloablative 53 perimenopausal women 53 randomized trials 53 androgens 52 uterine cancers 52 GIST tumors 52 leukemia AML 52 immunosuppressive therapies 52 advanced adenoma 52 calcium supplements 52 insulin glargine 52 docetaxel Taxotere 52 spironolactone 52 bezafibrate 52 sulfadoxine pyrimethamine 52 Gemcitabine 52 clopidogrel 52 Velcade bortezomib 52 breast irradiation 52 metastatic GIST 52 phosphate binders 52 ZOLINZA 52 venous thromboembolic events 52 BCG refractory 52 immunosuppressive 52 unfractionated heparin 52 calcium supplementation 52 HGS ETR1 52 prior chemotherapy regimens 52 Doxil 52 CoFactor 52 Capecitabine 52 spontaneous preterm delivery 52 undergo lumpectomy 52 plus progestin hormone 52 oral antidiabetic medication 52 mutated KRAS gene 52 reperfusion therapy 52 abiraterone acetate 52 antiemetics 52 APTIVUS 52 Cremophor 52 plasma uric acid 52 peginterferon alfa 52 invasive candidiasis 52 KRAS mutations occur 52 cetuximab Erbitux 52 estrogen progesterone 52 seminoma 52 malignant pleural mesothelioma 52 Bevacizumab 52 ovulatory cycles 52 lupus nephritis 52 thromboembolic events 52 neoplasia 52 Taxotere R 52 pazopanib 52 invasive lobular carcinoma 52 screening mammogram 52 HCV infected 52 T DM1 52 thrombolytic therapy 52 nonmelanoma skin cancer 52 minoxidil 52 unresectable stage 52 peginterferon alfa 2b 52 TAXOTERE R 52 serum testosterone 52 Sentinel node biopsy 52 radiotherapy 52 prostate cancer PCa 52 synthetic progestin 52 oral contraceptive pills 52 CR nPR 52 recurrent GBM 52 CHOP chemotherapy 52 chemoradiation therapy 52 prostate cancer HRPC 52 oral contraceptives 52 anti TNFs 52 folate intake 52 prophylactic mastectomies 52 levodopa therapy 52 axitinib 52 nilotinib 52 therapy 52 renal function 52 ovarian cancers 52 adjuvant hormonal therapy 52 sulfonylurea 52 citalopram Celexa 52 antidepressant medications 52 thyroid nodules 52 SLNB 52 breast endometrial 52 androgen deficiency 52 Revlimid lenalidomide 52 Kaplan Meier analysis 52 endometrial 52 Exemestane 52 premenopausal breast cancer 52 taxanes 52 estramustine 52 immunosuppressive regimens 52 pegylated interferon alfa 52 liver metastasis 52 autologous transplants 52 Surgical resection 52 glargine 52 oral contraception 52 spontaneous preterm birth 52 BRAF mutation 52 lymph node involvement 52 recurrent VTE 52 allogeneic SCT 52 docetaxel Taxotere ® 52 fluoropyrimidine 52 posaconazole 52 poorer prognosis 52 Pemetrexed 52 thalidomide Thalomid 52 INTELENCE 52 efalizumab 52 PREMPRO 52 caspofungin 52 dosage regimen 52 prostate carcinoma 52 Thal Dex 52 rhTSH 52 serum calcium levels 52 prostate cancer CaP 52 vulvar intraepithelial neoplasia 52 PegIntron 52 antiepileptic medications 52 NATRECOR R 52 Lapatinib 52 leflunomide 52 luteal 52 ovarian stimulation 52 median PFS 52 irregular menstrual cycles 52 leuprolide 52 bilateral mastectomy 52 diagnosed multiple myeloma 52 Zolinza 52 radical mastectomy 52 androgen ablation therapy 52 Paraplatin ® 52 pegylated interferon alfa 2a 52 CA4P 52 MGd 52 grade glioma 52 tenofovir emtricitabine 52 pharmacologic therapy 52 nephrectomy 52 neurologic progression 52 pegylated liposomal doxorubicin PLD 52 bowel resection 52 MAGE A3 ASCI 52 tumor histology 52 adenoma recurrence 52 medroxyprogesterone acetate 52 HER2 positive cancers 52 FIRMAGON 52 antitumor effect 52 postmenopausal hormones 52 CellCept 52 ovarian carcinoma 52 adjuvant therapies 52 bisphosphonate drugs 52 Adjuvant therapy 52 abciximab 52 squamous cell 52 antiarrhythmic drug 52 renal tumors 52 warfarin 52 indolent NHL 52 proton pump inhibitor 52 IFN beta 52 EUS FNA 52 suppressive therapy 52 trastuzumab DM1 52 NATRECOR ® 52 tesmilifene 52 NSAID 52 interferon ribavirin 52 panitumumab Vectibix 52 phenoxodiol 52 daunorubicin 52 Zevalin consolidation 52 relapsing remitting MS 52 etanercept 52 cholesterol lowering medication 52 YONDELIS 52 Rituximab 52 opioid therapy 52 colectomy 52 FOLFIRI alone 52 Navelbine 51 tumors 51 nelfinavir 51 thiazolidinedione 51 HER2 + 51 menopause 51 baseline mammogram 51 hormone therapy HT 51 degarelix 51 DOXIL 51 corticosteroid 51 multivitamin supplements 51 B7 H3 51 estrogen receptor ER 51 endoxifen 51 sertraline 51 intensive statin therapy 51 isoflavones 51 #mg dose [003] 51 Sandostatin LAR 51 metastases 51 dose escalation 51 Aromatase inhibitors 51 colorectal tumors 51 cediranib 51 anticoagulant therapy 51 pre cancerous lesions 51 cisplatin resistant 51 infusional 5-FU/LV 51 PREZISTA rtv 51 atherothrombotic events 51 Dronedarone 51 danazol 51 Ophena TM 51 Panzem R NCD 51 steroid prednisone 51 DCIS 51 colorectal adenoma 51 OPAXIO 51 abacavir lamivudine 51 gout flares 51 rituximab Rituxan 51 folate supplementation 51 TORISEL 51 KRAS mutant tumors 51 interferon IFN 51 rhGH 51 mg d 51 weekly subcutaneous injections 51 cilengitide 51 octreotide LAR 51 temozolomide TMZ 51 induce remission 51 tumor resection 51 menstrual migraine 51 thromboembolisms 51 zidovudine lamivudine 51 Femara letrozole 51 paclitaxel Taxol R 51 imatinib resistance 51 AstraZeneca Arimidex 51 Docetaxel 51 liver biopsies 51 menstrual bleeding 51 inhaled glucocorticoids 51 nitazoxanide 51 metastatic gastric 51 LY# [003] 51 metastatic hormone refractory 51 BARACLUDE 51 5-fluorouracil/leucovorin 51 hormone pills 51 hormonal contraceptives 51 pancreatic NET 51 paroxetine Paxil 51 Degarelix 51 advanced HER2 positive 51 coxibs 51 grade cervical intraepithelial 51 peg IFN 51 Allovectin 7 ® 51 estradiol 51 cyclophosphamide methotrexate 51 beta carotene supplements 51 5 Fluorouracil 51 IFN alpha 51 sunitinib malate 51 progesterone 51 sulphonylurea 51 breast tenderness 51 hot flashes 51 herceptin 51 panobinostat 51 cardiotoxicity 51 prednisone prednisolone 51 ribavirin RBV 51 Fludara ® 51 6 mercaptopurine 51 basal cell carcinomas 51 forodesine 51 trastuzumab Herceptin R 51 insulin detemir 51 Telintra 51 neoadjuvant radiation 51 relapsing remitting multiple sclerosis 51 estrogen progestin combination 51 randomized clinical trials 51 ZOMETA 51 lung tumors 51 inhaled corticosteroid 51 postoperative AF 51 partial nephrectomy 51 methotrexate MTX 51 dose regimens 51 Gemzar gemcitabine 51 moderate renal impairment 51 clopidogrel Plavix 51 curable cancers 51 EXJADE 51 OADs 51 LMWH 51 sorafenib Nexavar ® 51 antiangiogenic 51 advanced metastatic prostate 51 Folfox 51 iniparib BSI 51 EVISTA 51 fluvastatin 51 ovarian hormones 51 elagolix 51 carcinoid tumors 51 bevacizumab Avastin Genentech 51 oral ridaforolimus 51 luteal phase 51 APTIVUS ritonavir 51 Avastin Tarceva 51 atazanavir 51 gp# vaccine 51 NNRTIs 51 telaprevir dosed 51 platelet inhibitor 51 amiodarone 51 lasofoxifene 51 peginterferon alfa 2a 51 chemotherapy radiotherapy 51 ritonavir boosted lopinavir 51 sirolimus 51 gemcitabine carboplatin 51 urothelial cancer 51 NNRTI resistance 51 cangrelor 51 relieve menopausal symptoms 51 VICTRELIS 51 Targretin 51 epithelial ovarian 51 ELOXATIN 51 thiazide diuretic 51 clomiphene 51 ATACAND 51 myopathy rhabdomyolysis 51 nonvertebral fractures